Myeloid immune-checkpoint inhibition enters the clinical stage
Myeloid immune-checkpoint inhibition enters the clinical stage
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies...
Alternative Titles
Full title
Myeloid immune-checkpoint inhibition enters the clinical stage
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2159983892
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2159983892
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/s41571-018-0155-3
